Nebu-Flow secures additional $5.9 million to accelerate next generation respiratory pharmaceuticals
04/29/24, 1:18 PM
Location
glasgowMoney raised
$5.9 million
Industry
medical
biotechnology
health care
Investors
Conduit Eis Impact Fund, Ascension, Sis Ventures, Foresight Wae Technology, Scottish Enterprise, Scvc
Nebu-Flow has secured an additional $5.9 million of investment to accelerate the next generation of inhaled drugs for patients with respiratory disorders. The funding round was led by SCVC, a leading UK-based venture capital firm, and supported by Scottish Enterprise, Foresight WAE Technology, SIS Ventures, Ascension, and Conduit EIS Impact Fund.